Company: BDRX
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001214659-25-016821
Chunk: 34

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: F-1
Chunk 34
---
 $5.33 per Unit, assuming (i) no sale of any Pre-Funded Units and (ii) no exercise of the Series L Warrants 
 and the Placement Agent Warrants, after deducting the estimated placement agent fees and estimated offering expenses.                        |

The adjusted amounts shown
below are unaudited and represent management’s estimate. The as-adjusted information set forth in the table below is illustrative
only and will be adjusted based on the actual public offering price and other terms of this offering determined at pricing. The information
in this table should be read in conjunction with and is qualified by reference to the financial statements and notes thereto and other
financial information contained in this prospectus and incorporated by reference in this prospectus.

| (£ in thousands)          |     | As               
 of June 30, 2025 |        |     |             |        |
|:--------------------------|:----|:-----------------|-------:|:----|:------------|-------:|
|                           |     | Actual (audited) |        |     | As-Adjusted 
 (unaudited) |        |
| Cash and cash equivalents |     |                  |  4,036 |     |             | 15,809 |
| Long-term debt            |     |                  |     -- |     |             |     -- |
| Total equity              |     |                  | 11,436 |     |             | 23,209 |
| Total capitalization      |     |                  | 11,436 |     |             | 23,209 |

_____________

| (1) | A $1.00 increase or decrease in the assumed combined public offering                                                                          
 price of $5.33 per Unit, which is the last reported sale price of our Depositary Shares on the NASDAQ Capital Market on November 12, 2025,    
 would increase or decrease, as appropriate, our as-adjusted cash and cash equivalents, total equity and total capitalization by approximately 
 £2.39 million, assuming the number of units offered by us as set forth on the cover page of this prospectus remains the same,                 
 and after deducting the estimated placement agent fees and estimated offering expenses payable by us.                                         |

| (2) | All proceeds from the sale of the units have been reflected within Total equity for purposes of this table.                                 
 We will be required to complete an assessment of the accounting and valuation for such instruments, which may result in a portion of the    
 proceeds being